Professional Summary
Professional Overview
Dan Dolan is a seasoned financial executive with over 20 years of experience in the pharmaceutical and healthcare industries. He is currently the Head of Financial Planning and Analysis at Incyte, where he is responsible for driving strategic business decisions through data-driven insights and financial modeling.
Experience Summary
Current Role
As the Head of Financial Planning and Analysis at Incyte, Dan oversees the company's financial planning, budgeting, and forecasting processes. He collaborates closely with cross-functional teams to align financial strategies with business objectives, enabling informed decision-making and optimal resource allocation. Under his leadership, Incyte has achieved significant improvements in financial visibility and operational efficiency.
Career Progression
Prior to his current role, Dan held various finance leadership positions at prominent pharmaceutical companies, including Venatorx Pharmaceuticals, Nabriva Therapeutics, Radius Health, and Shire. In these roles, he demonstrated a track record of driving financial and operational transformation, leading high-performing teams, and implementing strategic initiatives that delivered measurable business impact.
As the Chief Financial Officer at Nabriva Therapeutics, Dan played a pivotal role in shaping the company's financial strategy, streamlining processes, and enhancing reporting capabilities, which contributed to the successful launch of their lead product.
Academic Background
Dan holds a Bachelor of Science in Accounting from the University of Scranton and is a Certified Public Accountant (CPA).
Areas of Expertise
- Financial planning and analysis
- Budgeting and forecasting
- Strategic decision support
- Financial modeling and reporting
- Cross-functional collaboration
- Team leadership and development
- Pharmaceutical industry experience
Professional Impact
During his tenure at Radius Health, Dan led the implementation of a global financial planning and analysis framework, which resulted in a 25% improvement in budgeting accuracy and a 20% reduction in reporting cycle times. At Shire, he spearheaded the integration of financial systems and processes following a major acquisition, ensuring seamless financial integration and operational continuity.
Conclusion
With his extensive experience in the pharmaceutical industry, strong financial acumen, and proven leadership capabilities, Dan Dolan is poised to drive continued success at Incyte. He is committed to leveraging data-driven insights to support strategic decision-making and contribute to the company's long-term growth and profitability.
